ORIGINAL PAPER

Injectable platelet-rich fibrin influences the behavior of gingival mesenchymal stem cells

SOFIA IOZON¹⁾, GABRIELA VALENTINA CARACOSTEA²⁾, EMŐKE PÁLL³⁾, OLGA ȘORIȚĂU⁴⁾,
IONUȚ DANIEL MĂNĂLOIU⁵⁾, ADRIANA-ELENA BULBOACĂ⁶⁾, MIHAELA LUPȘE⁷⁾,
CARMEN MIHAELA MIHU⁸⁾, ALEXANDRA LIVIA ROMAN⁹⁾

¹⁾PhD Student, Department of Periodontology, Faculty of Dental Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

²⁾Department of Obstetrics and Gynecology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

³⁾Life Science Institute, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania

⁴⁾Laboratory of Radiotherapy, Tumor and Radiobiology, Prof. Dr. Ion Chiricuță Oncology Institute, Cluj-Napoca, Romania

⁵⁾Dental Medicine Private Practice, Cluj-Napoca, Romania

⁶⁾Department of Pathophysiology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

⁷⁾Department of Infectious Diseases, Faculty of Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

⁸⁾Discipline of Histology, Department of Morphological Sciences, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

⁹⁾Department of Periodontology, Faculty of Dental Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Abstract

In this study, we examined the effects of injectable platelet-rich fibrin (iPRF) on proliferation and osteodifferentiation in mesenchymal stem cells (MSCs) isolated from human gingiva. Gingival MSCs (gMSCs) were grown in experimental culture media with different concentrations of iPRF [5%, 10%, and replacement of fetal calf serum (FCS) in the standard media with 10% iPRF–10% iPRF-FCS]. Immunophenotyping of gMSCs was performed after seven days by flow cytometry, and their proliferation was examined after three and seven days using the Cell Counting Kit-8 method. After 14 days in culture, spontaneous osteogenic differentiation of gMSCs was evaluated via real-time polymerase chain reaction. All gMSCs were positive for cluster of differentiation (CD) 105, CD73, CD90, and CD44, and negative for CD34/45, CD14, CD79a, and human leukocyte antigen, DR isotype (HLA-DR). Reduced expression of some surface antigens was observed in the gMSCs grown in 10% iPRF-FCS medium compared to the other groups. After three days, gMSCs grown in 10% iPRF had proliferated significantly less than the other groups. After seven days, proliferation was significantly higher in the 5% iPRF cells compared to the control, while proliferation in the 10% iPRF and 10% iPRF-FCS groups was significantly lower. No spontaneous osteogenic differentiation was observed in the presence of iPRF, as observed by low runt-related transcription factor 2 (*RUNX2*) expression. Some expression of secreted protein acidic and cysteine rich (*SPARC*) and collagen 1 alpha (*COL1A*) was observed for all the gMSCs regardless of the culture medium composition. gMSCs grown in 10% iPRF had significantly lower *SPARC* expression. In conclusion, 5% iPRF stimulated gMSC proliferation, and an excessively high concentration of iPRF can impair osteogenic induction.

Keywords: mesenchymal stem cells, platelet-rich fibrin, growth factors, proliferation, differentiation, gingiva.

Introduction

Periodontitis is a prevalent disease [1], which induces the destruction of tooth-supporting tissues and affects oral function and quality of life. Although highly expected [2, 3], regeneration of lost periodontal tissues remains unpredictable. Current biomaterials used in periodontal treatment [3, 4] generally induce repair [3], and could be associated with risks of disease transmission [5].

New periodontal therapies using autologous mesenchymal stem cells (MSCs) [6] of different oral origin [7–13] may stimulate periodontal regeneration, but they are associated with certain drawbacks that limit the clinical use of *ex vivo*-manipulated MSCs [14]. Growth factors could eventually be used to stimulate the intrinsic regenerative capacity of the periodontal tissues [15].

Platelet concentrates are blood-derived products containing a 3- to 5-fold higher concentration of platelets compared to whole blood and contain many growth factors essential for bone growth and regeneration [16]. Platelet concentrates are cost effective, available in large quantities, reduce inflammation, provide healing, are non-immunogenic [16] and could replace fetal calf serum (FCS) in culture media [17]. Different production protocols have resulted in different leukocyte content and fibrin matrix architecture and density of the products [18–20].

Platelet-rich plasma (PRP) enhanced osteoprogenitor cells [21] and induced positive *in vitro* and oral surgery outcomes [22–24], but a rapid release of growth factors has also been reported [25]. Moreover, some hazards are associated with bovine thrombin and other additives used

to handle PRP [26]. The development of platelet-rich fibrin (PRF) as a second generation of platelet concentrate, which is rich in various growth factors and capable of releasing them continuously and slowly, offers a solution for appropriate growth factor delivery [27]. Moreover, PRF is produced without the use of anticoagulants or coagulation factors [28] and, due to reduced centrifugation G-force, it induces an increase in leukocyte numbers [29] and growth factor concentrations [25]. These products both share the same principle of preparation through activation of the intrinsic coagulation cascade [30]. PRF products have complete immune biocompatibility and induce rapid angiogenesis of tissues, leading to faster wound healing [31]. Platelets harbor potent growth factors important for tissue regeneration and MSC maintenance [32, 33], such as platelet-derived growth factors (PDGFs), vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF- β), and insulin-like growth factor (IGF) [34, 35], which can be released only after platelet aggregation [36]. The leukocytes in PRF-based biomaterials improve regeneration [37], fight infection, significantly influence the biological behavior of these products [38] and contribute to the cross-talk between local cells [39, 40].

Initially, PRF was designated as leukocyte- and PRF (L-PRF) [28]. The preparation protocol was later modified to produce injectable PRF (iPRF) [34]. iPRF [34] is a recently developed leukocyte-enriched platelet concentrate, which could better assist tissue regeneration and wound healing phenomena [41]. Although initially in a liquid phase, iPRF forms a dynamic fibrin gel embedding platelets, leukocytes, type 1 collagen (COL1), osteocalcin (OC), and growth factors [38] and providing slow release of growth factors [42].

iPRF may stimulate intrinsic tissue regeneration capacity by stimulating the proliferation of human MSCs *in vitro* [18, 43–46] and by inducing osteogenic differentiation of MSCs [18, 44, 46, 47]. Additionally, it has been reported that iPRF has greater antimicrobial activity against several periodontal pathogens [48]. When implanted along with a bone graft, iPRF increases the incorporation of the graft and the signaling local molecules [49]. Despite these promising results, a more comprehensive physicochemical and biological characterization of iPRF is needed before its clinical use in dentistry. Currently, literature describing the use of iPRF in dentistry is scarce [41, 42, 50–52]. The current data seems to suggest that iPRF would be beneficial when used in periodontal-implant procedures [53], but other studies are needed to fully characterize its behavior and reveal any added advantages or drawbacks [42].

Oral MSCs are important players in the process of periodontal regeneration, and stimulation of these cells by surgical approaches is highly beneficial and expected. Using growth factors to promote periodontal regeneration is an important strategy for the reestablishment of structure and function in periodontitis patients. iPRF is a new type of platelet concentrate that may provide improved periodontal regeneration due to its supra-physiological doses of growth factors and cells. The aim of the present study was to observe the effects of iPRF on MSCs isolated from human gingiva, specifically in

terms of proliferation and osteodifferentiation capability in comparison with standard growing conditions. Our null hypothesis is that there will be no differences in gingival MSCs (gMSCs) grown in different concentrations of iPRF-supplemented culture media *versus* standard culture medium.

Materials and Methods

Study design

The protocol used in this study was approved by the Ethics Board of the Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania (Nos. 359/13.10.2014 and 330/26.07.2018). Before signing the informed consent, the patients from which tissue samples and blood were collected were given explanations regarding the study protocol and procedural details. This study protocol adhered to the principles outlined in the Declaration of Helsinki on experimentation involving human subjects. The experiments using stem cells were conducted in accordance with European Union and national laws.

MSCs previously isolated from gingival tissues and fully characterized [12] were used in the present experiment. Experimental culture media were prepared by supplementing the standard culture medium with different concentrations of iPRF. gMSCs were grown in experimental culture media for seven and 14 days, and then their surface antigen expression, proliferation capacity, and eventually spontaneous osteogenic differentiation capacity were assessed. Immunophenotyping of surface antigens was performed by flow cytometry, and the proliferation capacity of gMSCs was tested using the Cell Counting Kit-8 (CCK-8) method. The spontaneous osteogenic differentiation of gMSCs cultivated in different experimental culture media for 14 days was evaluated through real-time polymerase chain reaction (RT-PCR) analysis of gene expression. gMSCs cultivated in standard culture medium were used for the control group. All experiments were performed in triplicate.

Preparation of iPRF and experimental culture media

All blood samples were obtained from a 27-year-old female volunteer donor who was a member of the research team (SI), a non-smoker, had no systemic disease, had no history of using antiplatelet or anticoagulant medication, and had given informed consent for the procedure.

The procedure was performed every three days, corresponding to culture medium replacement, for a total of five times. Each time, four tubes (iPRF Collection Tubes, Process for PRF, Nice, France) containing 10 mL of whole blood without anticoagulant were centrifuged according to a pre-established protocol [42, 54] at 700 rpm for three minutes (60 $\times$ g), at room temperature, in a Duo Centrifuge (Process for PRF, Nice, France) (Figure 1A). After centrifugation, the whole blood was separated into three main parts: a yellow upper part, a buffy coat in the middle, and a red blood cell-containing lower part (Figure 1B). An automatic pipette was used to collect the iPRF (approximately 1 mL from the upper layer). Particular attention was given to collect only the superficial yellow coat (above the leukocyte-rich buffy coat) because

even minimal changes in the fractionation protocol could alter the physical and biological properties of the final product [49]. The process was performed as quickly as possible.

Figure 1 – Preparation of iPRF: (A) Duo Centrifuge; (B) iPRF tube after centrifugation: iPRF is the upper yellow layer. iPRF: Injectable platelet-rich fibrin.

The three experimental culture media were prepared for the experiment as follows: two media were prepared by supplementing the basal culture medium [Dulbecco's Modified Eagle's Medium/Nutrient Mixture F-12 Ham (DMEM/F12), Sigma-Aldrich, St. Louis, MO, USA; plus 10% FCS, EuroClone, Milano, Italy; plus 1% antibiotic/antimycotic, Gibco Life Technologies, Paisley, UK] with iPRF in two concentrations – 5% (5% iPRF) and 10% (10% iPRF). The third propagation medium was obtained by replacing FCS in basal medium with 10% iPRF (10% iPRF-FCS).

Gingival MSCs

For this experiment, gMSCs obtained from a previously isolated and fully characterized cell line were used [12].

The gMSCs were obtained from a 26-year-old woman from normal gingival wastes removed during a tooth extraction. After isolation, cells were kept in complete DMEM/F12 culture medium containing 20% fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Gibco Life Technologies, Paisley, UK).

After several passages and characterization (immunophenotyping of cell surface antigens by flow-cytometry, transcription factors by immunocytochemical staining and the stemness gene expression by RT-PCR), the cell line was cryopreserved. The characterization of putative MSCs isolated from gingival tissues followed the achievement of the standard minimal criteria suggested by the *International Society for Cellular Therapy* [55], as well as some supplementary investigations. Cells were characterized by immunophenotyping of cell surface antigens [positivity for cluster of differentiation (CD) 90, CD105, CD73 and negative expression of CD45, CD34, CD14, CD79, and human leukocyte antigen, DR isotype (HLA-DR)] and transcription factors, stemness gene expression [Nanog homeobox (*NANOG*) and sex determining region Y (SRY)-box 2 (*SOX2*)], as well as by trilineage mesenchymal differentiation potential (osteogenic, chondrogenic, adipogenic) [12]. After thawing, passage 4 cells were expanded until passage 6 using a protocol

detailed elsewhere [12, 56]. Briefly, 1.5×10^6 gMSCs were cultured in normal propagation DMEM/F12 medium (Gibco Life Technologies, Paisley, UK), supplemented with 10% FCS and 1% antibiotic/antimycotic (Gibco Life Technologies, Paisley, UK), and plated in a 25 cm² tissue flask in a humidified atmosphere with 5% CO₂, at 37°C. After reaching 70–80% confluence (five days), the monolayer cell culture was trypsinized using 0.25% Trypsin–Ethylenediaminetetraacetic acid (EDTA) solution (Sigma-Aldrich, St. Louis, MO, USA) for 10 minutes, at 37°C, and was passaged at a 1:4 ratio until passage 6. The medium was replaced every three days.

Immunophenotyping of gMSCs

After passage 6, the basal culture medium was exchanged with experimental culture media. After seven days of growing in experimental media, gMSCs were characterized by immunophenotype analysis as described previously [12]. The following monoclonal antibodies (BD Biosciences, San Jose, CA, USA) were used according to the manufacturer's recommendations: CD105 Allophycocyanin-A (APC-A), CD73 Fluorescein isothiocyanate-A (FITC-A), CD90 Forward scatter-A (FSC-A), CD44 APC-A, CD34/45 Phycoerythrin-A (PE-A), CD14 FITC-A, CD79a PE-A, and HLA-DR PE-A. Negative and positive controls were used. The cells were trypsinized (0.25% Trypsin–EDTA solution, Sigma-Aldrich, St. Louis, MO, USA), washed twice with phosphate-buffered saline (PBS), and then fixed in 4% paraformaldehyde (Fluka, Buchs, Switzerland) for 15 minutes. 1×10^5 cells per sample were stained at room temperature with isotype control monoclonal antibodies (mAbs) and then incubated with 3% FBS albumin. The cells were washed twice with PBS containing 2% FBS and centrifuged for six minutes, at 1800 rpm. The cells were resuspended in 500 µL of cell wash solution (BD Biosciences, San Jose, CA, USA). A BD FACSCanto™ II 6-color flow cytometer (BD Biosciences, San Jose, CA, USA) and BD FACSDiva™ software (version 6.1.3) were used for cytometric analysis [10].

CCK-8 proliferation assay

A CCK-8 (Sigma Aldrich, St. Louis, MO, USA) was used for this assay, after three and seven days of growing gMSCs in experimental media. To evaluate the proliferation of gMSCs, 100 µL of each cell suspension (5000 cells/well) was cultivated in 96-well plates (Thermo Fisher Scientific, Waltham, MA, USA). After three and seven days, a total volume of 10 µL of the CCK-8 solution was added to each well. The plate was then incubated for four hours. The optical densities of each well were read at 450 nm with a BioTek Synergy 2 microplate reader (Winooski, VT, USA).

RT-PCR analysis

Evaluation of osteogenic gene expression was assessed by RT-PCR after 14 days of gMSC culture in experimental media. The cells were harvested in Trizol and processed for total ribonucleic acid (RNA) extraction using the classical method with phenol–chloroform. The obtained RNA was evaluated quantitatively using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and qualitatively with an Agilent

2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only RNAs which had a RNA integrity number (RIN) greater than 8 were used in subsequent analyses. From each sample, 500 ng total RNA was used for complementary deoxyribonucleic acid (cDNA) synthesis with the Transcriptor First Strand cDNA Synthesis Kit according to the manufacturer's protocol (Hoffmann–La Roche, Basel, Switzerland). cDNA was then 1:10 diluted and amplified with the LightCycler® TaqMan® Master Kit using a LightCycler 480 (Hoffmann–La Roche, Basel, Switzerland). *Ct* values were calculated using the Absolute

Quantification/Second Derivative Maximum method, and the expression levels for each gene were normalized to *18S* housekeeping gene levels. Fold changes were calculated using the ΔCt method relative to the control samples. Genes with *Ct* values above 35 were considered to be not expressed. Expression levels of collagen 1 alpha (*COL1A*), runt-related transcription factor 2 (*RUNX2*), secreted protein acidic and cysteine rich (*SPARC*; osteonectin), Nanog homeobox (*NANOG*), bone morphogenetic protein 4 (*BMP4*), and *18S* were analyzed using the primer sequences listed in Table 1.

Table 1 – Primer sequence used for gene expression analysis of gMSCs

Gene	Forward sequence (5'→3')	Reverse sequence (5'→3')
<i>COL1A</i>	CAGGCAAACCTGGTGAACA	CTCGCCAGGGAAACCTCT
<i>RUNX2</i>	GCCTAGGCACATCGGTGA	CCGTCCATCCACTCTACCAC
<i>SPARC</i>	TTCCCTGTACACTGGCAGTTC	AATGCTCCATGGGGATGA
<i>NANOG</i>	ATGCCTCACACGGAGACTGT	CAGGGCTGTCCTGAATAAGC
<i>BMP4</i>	GAGGAGTTTCCATCACGAAGA	GCTCTGCCGAGGAGATCA
<i>18S</i>	GCAATTATTCCCATGAACG	GGGACTTAATCAACGCACGC

gMSCs: Gingival mesenchymal stem cells; *COL1A*: Collagen 1 alpha; *RUNX2*: Runt-related transcription factor 2; *SPARC*: Secreted protein acidic and cysteine rich (osteonectin); *NANOG*: Nanog homeobox; *BMP4*: Bone morphogenetic protein 4; A: Adenine; C: Cytosine; G: Guanine; T: Thymine.

The primers' design was performed at the laboratory where the RT–PCR analysis was made, using Universal ProbeLibrary Assay Design Center, Roche Life Science, software.

Statistical analysis

Data from the CCK-8 analysis were summarized as mean $\pm$ standard deviation (SD). The comparisons between the control group and each experimental group were evaluated with a Mann–Whitney test at a significance level of 5%. The data were plotted as individual values (circles) and the median (the line) using the template provided by Weissgerber *et al.* [57].

RT–PCR assays were analyzed with GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA). The differences were considered statistically significant at $p < 0.05$.

Results

Characterization of surface markers of gMSCs grown in iPRF-conditioned experimental media

In this experiment, passage 6 gMSCs were grown for seven days in experimental media for evaluating surface

antigen make-up (Figure 2). Under optic microscopy, gMSCs grown in all experimental conditions were firmly attached to the plastic culture plates and showed a fibroblast-like morphology with an increased proliferation rate. From passage 4 to passage 6, the cells maintained their proliferation rates without changing their morphology.

The *in vitro* expression of gMSC surface markers was evaluated by flow cytometry. gMSCs were assessed for several MSC surface antigens proposed as possible standards, as well as one supplementary antigen. The results revealed relatively similar expression patterns of surface markers across all four groups. Irrespective of the media composition, all gMSCs were positive for CD105, CD73, CD90, and CD44, and negative for CD34/45, CD14, CD79a, and HLA-DR, indicating a MSC phenotype (Table 2).

However, some differences in antigen expression were observed. A reduced expression of some positive surface antigens (CD105, CD73, and CD90) was recorded for gMSCs grown in 10% iPRF-FCS medium compared to the other groups. Additionally, an increased expression of CD79a, which is usually not expressed on gMSCs, was also observed in this group.

Table 2 – Flow cytometry analysis of passage 6 gMSCs grown in different experimental media

Experimental medium	Surface antigens [%] of gMSCs							
	CD105 APC-A*	CD73 FITC-A†	CD90 FSC-A†	CD44 APC-A	CD34/45 PE-A§	CD14 FITC-A	CD79a PE-A	HLA-DR PE-A
5% iPRF	93	95.1	95.3	95.5	0.1	0	3.1	0
10% iPRF	94.1	91.1	97.1	94.8	0.1	0	4.1	0
10% iPRF-FCS	88.2	79.2	86.6	94.9	0.1	0	8.6	0
Control	91.3	90.3	97.4	96.8	0.1	0	0.5	0.2

gMSCs: Gingival mesenchymal stem cells; iPRF: Injectable platelet-rich fibrin; FCS: Fetal calf serum; CD: Cluster of differentiation; APC-A*: Allophycocyanin-A; FITC-A†: Fluorescein isothiocyanate-A; FSC-A†: Forward scatter-A; PE-A§: Phycoerythrin-A; HLA-DR: Human leukocyte antigen, DR isotype.

Figure 2 – Microscopic aspects of gMSCs after seven days of culture in experimental media (10×): (A) 5% iPRF; (B) 10% iPRF; (C) 10% iPRF-FSC; (D) Control. gMSCs: Gingival mesenchymal stem cells; iPRF: Injectable platelet-rich fibrin; FCS: Fetal calf serum.

CCK-8 proliferation assay

To assess the effects of iPRF on proliferation in gMSCs, proliferation after three and seven days of culture in iPRF-supplemented media was investigated. Generally, iPRF stimulation resulted in significantly lower proliferation as revealed by optical density values after three days of culture: 0.773 ± 0.045 (control conditions) vs. 0.732 ± 0.021 (5% iPRF) vs. 0.64 ± 0.04 (10% iPRF) vs. 0.568 ± 0.209 (10% iPRF-FCS). After three days, the control group had the highest rate of proliferation (Figure 3), with no significant differences between the control and 5% iPRF group (Mann–Whitney test: Z-statistic = 1.09) or the 10% iPRF-FCS group (Mann–Whitney test: Z-statistic = 1.53), but with a significantly lower proliferation in the 10% iPRF group (Mann–Whitney test: Z-statistic = 1.96) (Figure 4A).

After seven days, the optical density values indicating cell proliferation were as follows: 1.338 ± 0.123 (control group) vs. 1.493 ± 0.04 (5% iPRF) vs. 0.97 ± 0.068 (10% iPRF) vs. 0.741 ± 0.078 (10% iPRF-FCS). The cell proliferation was significantly higher in the 5% iPRF group compared to the control group (Mann–Whitney test: Z-statistic = -1.96), while the proliferation in the 10% iPRF (Mann–Whitney test: Z-statistic = 1.96) and 10% iPRF-FCS (Mann–Whitney test: Z-statistic = 1.96) groups was significantly lower (Figure 4B).

Characterization of osteogenic markers

To evaluate the effect of iPRF on spontaneous osteogenic differentiation of gMSCs, *COL1A*, *RUNX2*, *SPARC*, *NANOG*, and *BMP4* expression was measured by RT-PCR after 14 days of gMSC culture in experimental media. An overall decrease in the expression of all investigated osteogenic genes was observed for gMSCs grown in iPRF-containing media in comparison with the controls. A significantly lower expression of *RUNX2* was observed in gMSCs grown in 10% iPRF and 10% iPRF-FCS in comparison with gMSCs grown in standard culture medium. Also, a significantly lower expression of *SPARC* was observed in gMSCs grown in 10% iPRF in comparison with the controls (Figure 5).

Discussions

PRF is an autologous fibrin-based living biomaterial rich in growth factors that can modulate regenerative processes [58], possessing improved biological properties compared to other platelet concentrates. In this study, MSCs of gingival origin at passage 6 were grown in experimental iPRF-based culture media in order to observe the influence of the platelet concentrate on cell proliferation, stemness, and osteogenic differentiation. To the best of our knowledge, this is the first study investigating the influence of iPRF on gMSCs. iPRF was chosen because this product demonstrated the ability to release higher

concentrations of growth factors and to induce improved cell behavior *versus* the standard PRP variants [42]. Moreover, the process used to produce iPRF is completely

natural, with no use of anticoagulant during blood harvest nor bovine thrombin and calcium chloride for platelet activation and fibrin polymerization [42].

Figure 3 – Proliferation after three and seven days of culture in iPRF-containing media. The height of the column indicates the value of arithmetic mean for optical density, and the whiskers correspond to the standard deviation. CTRL: Control; iPRF: Injectable platelet-rich fibrin; FCS: Fetal calf serum.

Figure 4 – Proliferation of gMSCs grown in the investigated culture media: (A) After three days; (B) After seven days. The circles correspond to the individual values while the line corresponds to the value of the median. gMSCs: Gingival mesenchymal stem cells; CTRL: Control; iPRF: Injectable platelet-rich fibrin; FCS: Fetal calf serum.

Figure 5 – RT-PCR results. Relative gene expression in gMSCs grown in iPRF-supplemented culture media. gMSCs: Gingival mesenchymal stem cells; CTRL: Control; iPRF: Injectable platelet-rich fibrin; FCS: Fetal calf serum; COL1A: Collagen 1 alpha; RUNX2: Runt-related transcription factor 2; SPARC: Secreted protein acidic and cysteine rich (osteonectin); NANOG: Nanog homeobox; BMP4: Bone morphogenetic protein 4.

After three days of culture, a decrease in proliferation was observed in gMSCs grown in experimental media, although significance was only reached in the 10% iPRF group. Five percent iPRF enhanced gMSC proliferation

after seven days of cultivation while retaining cell stemness. After seven days of culture, 10% iPRF or the replacement of FCS with 10% iPRF significantly decreased the proliferation of the gMSCs. The higher concentration of iPRF

seems to have an inhibitory effect on gMSC proliferation. This is in agreement with other studies, which reported that higher concentrations (10%, 20%) of PRP induced significantly less proliferation compared to lower concentrations (2%, 5%) [59, 60] possibly due to the inhibitory effect of prostaglandin E2 released by the platelet concentrate [61]. Two percent PRP seems to be the ideal concentration for the growth of exfoliated deciduous tooth MSCs [60]. The most surprising results in the current study were those of the 3-day cell proliferation assay. We would have expected a proliferative benefit induced by at least the lower concentration of iPRF, since it has been demonstrated that PRF products release high quantities of growth factors and matrix proteins for at least seven days [62]. Moreover, previous studies have reported that iPRF significantly stimulates *in vitro* proliferation of MSCs in a dose-dependent manner [18, 46] and stimulates proliferation of gingival fibroblasts [41]. It is likely that the induction of proliferation by iPRF needs time, thus explaining our results and further demonstrating the slow-release of growth factors by iPRF. One limitation of this study is that we did not use iPRF concentrations lower than 5%, and other studies have reported that 5% PRP inhibited cell proliferation [63]. However, the most beneficial iPRF concentration for inducing proliferation is still controversial [44, 59, 60, 63].

Some studies have suggested that FBS can be replaced with PRP to induce stem cell proliferation [14], with 15% PRP having the highest proliferation rate [14, 64]. The results of our study do not sustain this idea.

After seven days of culture in iPRF-containing media, a decrease in the expression of several cell surface markers was generally observed, with a more important decrease recorded for CD105, CD73, and CD90 in the 10% iPRF-FCS group. Increased CD79a positivity was seen in the 10% iPRF-FCS group. CD79 is a disulfide-linked heterodimer found on the surface of B-lineage leukocytes and its expression is likely caused by leukocytes in the iPRF conditioned media [18].

RT-PCR was used to measure important osteogenesis-related genes, including *COL1A*, *RUNX2*, and *SPARC*. We did not observe any spontaneous osteogenic differentiation in the presence of iPRF, as revealed by only low expression of *RUNX2* in all the experimental groups and a significantly lower expression of *RUNX2* in the gMSCs grown in 10% iPRF and 10% iPRF-FCS compared to the other groups. Expression of *SPARC* and *COL1A* was recorded for all gMSCs regardless of the culture medium composition. Additionally, a significantly lower expression of *SPARC* was observed in the gMSCs grown in 10% iPRF. These specific genes are expressed at different stages of osteogenic differentiation. During bone development, *RUNX2* plays an essential role in the direct activation of other osteogenic genes, including *COL1* [65]. *COL1*, which is the most predominant extracellular protein in bone, initially provides a structural framework for inorganic deposits [66]. *RUNX2* is a key factor that leads to MSC osteoblastic differentiation [60] and functions at the center of many other osteogenesis-related pathways, including the BMP signaling pathway [67].

Our study revealed some seemingly conflicting results, such as high co-expression of *NANOG* and *BMP4* genes implicated in pluripotency and self-renewal on one hand,

and on the other some osteogenic gene expression in the MSC control cell cultures and 5% iPRF cultures. It is well known that gMSCs have a unique developmental origin (perifollicular mesenchyme and neural crest) [68], which is responsible for their high self-renewal capacity and proliferation rates compared to bone-marrow derived MSCs. Pluripotency markers, including octamer-binding transcription factor-3/4 (*OCT-3/4*), *NANOG*, and *SOX2*, are expressed by gMSCs in a manner very similar to dental pulp pluripotent-like stem cells, and their long-term telomerase expression is similar to that of embryonic stem cells [69]. *BMP4* was initially described as a major effector of the self-renewal mechanisms in mouse embryonic stem cells, accomplished by inhibition of both the extracellular receptor kinase and p38 mitogen-activated protein kinase pathway [70]. The osteoblastic differentiation process is connected to the p38-mediated phosphorylation and extracellular receptor kinase pathway, which promotes the progression of osteogenesis by enhancing the activity or expression of osteoblast-specific transcription factor genes, such as *RUNX2* [71]. These observations may explain the lower expression of osteogenic genes (*COL1A*, *RUNX2* and *SPARC*) in our samples cultivated with 10% iPRF.

The results of studies examining the effects of iPRF on osteogenic differentiation of MSCs are conflicting. Our results are consistent with studies showing that platelet concentrates appear to be inefficient in promoting osteogenic differentiation [5, 45, 72, 73]. Other studies have conversely reported that iPRF promotes significant proliferation and differentiation of bone MSCs [18, 54] in a dose-dependent manner.

Our study rejects the null hypothesis, since significant differences in terms of proliferation and gene expression in the different gMSC groups were observed. The results of the present study should be regarded with caution. It seems that proliferation and osteogenic differentiation are two processes which are activated at different concentrations of platelet concentrates. Ten percent PRF increases the proliferation of MSCs, but 1% PRF is recommended for bone wound healing and tissue engineering [44]. Moreover, there is heterogeneity in stem cell properties and in the composition of platelet concentrates due to intra-patient variation [5]. In addition, the true periodontal microenvironment was not mirrored in the present study and thus we could not measure the biological benefits of iPRF on gMSCs *in vivo*.

Conclusions

Five percent iPRF stimulated gMSC proliferation after seven days of culture but not after three days, which could indicate that a certain time is needed for growth factors to induce local stimulation. This highlights the importance of using slow-releasing growth factor products, such as iPRF, in order to assure biological stimulation for clinical purposes. Additionally, an excessively high concentration of iPRF could impair osteogenesis. Further studies are needed before iPRF can be implemented in clinical dental practice.

Conflict of interests

The authors declare that they have no conflict of interests.

Acknowledgments

The costs of the research were partially covered by the Iuliu Hațieganu University of Medicine and Pharmacy Scientific Grant contract Nos. 1680/49/19.01.2018 and 1530/31/18.01.2019. The authors are grateful to Sorana Daniela Bolboacă, Professor, PhD for statistical analysis, Adrian Florea, Associate Professor, PhD for assistance in image processing and Claudia Diana Gherman, Associate Professor, PhD for genetic analysis. This manuscript has been copyedited by native English speakers, with a related medical background by BioMed Proofreading® LLC.

Authors' contribution

Sofia Iozon, Gabriela Valentina Caracostea and Emöke Páll equally contributed to the present study and can be regarded, therefore, as being main authors.

References

- [1] Kassebaum NJ, Smith AGC, Bernabé E, Fleming TD, Reynolds AE, Vos T, Murray CJL, Marcenes W; GBD 2015 Oral Health Collaborators. Global, regional, and national prevalence, incidence, and disability-adjusted life years for oral conditions for 195 countries, 1990–2015: a systematic analysis for the global burden of diseases, injuries, and risk factors. *J Dent Res*, 2017, 96(4):380–387. <https://doi.org/10.1177/0022034517693566> PMID: 28792274 PMCID: PMC 5912207
- [2] Rios HF, Bashutski JD, McAllister BS, Murakami S, Cobb CM, Chun YHP, Lin Z, Mandelaris GA, Cochran DL. Emerging regenerative approaches for periodontal reconstruction: practical applications from the AAP Regeneration Workshop. *Clin Adv Periodontics*, 2015, 5(1):40–46. <https://doi.org/10.1902/cap.2015.140052> PMID: 26146593 PMCID: PMC4486332
- [3] Sculean A, Nikolidakis D, Nikou G, Ivanovic A, Chapple ILC, Stavropoulos A. Biomaterials for promoting periodontal regeneration in human intrabony defects: a systematic review. *Periodontol* 2000, 2015, 68(1):182–216. <https://doi.org/10.1111/prd.12086> PMID: 25867987
- [4] Bottino MC, Thomas V. Membranes for periodontal regeneration – a materials perspective. *Front Oral Biol*, 2015, 17: 90–100. <https://doi.org/10.1159/000381699> PMID: 26201279
- [5] Fernandes G, Yang S. Application of platelet-rich plasma with stem cells in bone and periodontal tissue engineering. *Bone Res*, 2016, 4:16036. <https://doi.org/10.1038/boneres.2016.36> PMID: 28018706 PMCID: PMC5153571
- [6] Gneccchi M, Danieli P, Malpasso G, Ciuffreda MC. Paracrine mechanisms of mesenchymal stem cells in tissue repair. *Methods Mol Biol*, 2016, 1416:123–146. https://doi.org/10.1007/978-1-4939-3584-0_7 PMID: 27236669
- [7] Gronthos S, Mankani M, Brahimi J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) *in vitro* and *in vivo*. *Proc Natl Acad Sci U S A*, 2000, 97(25):13625–13630. <https://doi.org/10.1073/pnas.240309797> PMID: 11087820 PMCID: PMC17626
- [8] Morsczeck C, Petersen J, Völlner F, Driemel O, Reichert T, Beck HC. Proteomic analysis of osteogenic differentiation of dental follicle precursor cells. *Electrophoresis*, 2009, 30(7): 1175–1184. <https://doi.org/10.1002/elps.200800796> PMID: 19288589
- [9] Pall E, Cenariu M, Kasaj A, Florea A, Soancă A, Roman A, Georgiu C. New insights into the cellular makeup and progenitor potential of palatal connective tissues. *Microsc Res Tech*, 2017, 80(12):1270–1282. <https://doi.org/10.1002/jemt.22925> PMID: 28816410
- [10] Roman A, Soancă A, Florea A, Páll E. *In vitro* characterization of multipotent mesenchymal stromal cells isolated from palatal subepithelial tissue grafts. *Microsc Microanal*, 2013, 19(2): 370–380. <https://doi.org/10.1017/S143192761201433X> PMID: 23425444
- [11] Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahimi J, Young M, Gehron Robey P, Wang CY, Shi S. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet*, 2004, 364(9429):149–155. [https://doi.org/10.1016/S0140-6736\(04\)16627-0](https://doi.org/10.1016/S0140-6736(04)16627-0) PMID: 15246727
- [12] Soancă A, Lupse M, Moldovan M, Pall E, Cenariu M, Roman A, Tudoran O, Surlin P, Șorîțau O. Applications of inflammation-derived gingival stem cells for testing the biocompatibility of dental restorative biomaterials. *Ann Anat*, 2018, 218:28–39. <https://doi.org/10.1016/j.aanat.2018.02.009> PMID: 29604386
- [13] Sonoyama W, Liu Y, Yamaza T, Tuan RS, Wang S, Shi S, Huang GTJ. Characterization of the apical papilla and its residing stem cells from human immature permanent teeth: a pilot study. *J Endod*, 2008, 34(2):166–171. <https://doi.org/10.1016/j.joen.2007.11.021> PMID: 18215674 PMCID: PMC 2714367
- [14] Tavakolinejad S, Khosravi M, Mashkani B, Bideskan AE, Mossavi NS, Parizadeh SMR, Alamdari DH. The effect of human platelet-rich plasma on adipose-derived stem cell proliferation and osteogenic differentiation. *Iran Biomed J*, 2014, 18(3):151–157. <https://doi.org/10.6091/ibj.1301.2014> PMID: 24842141 PMCID: PMC4048479
- [15] Carmagnola D, Pellegrini G, Dellavia C, Rimondini L, Varoni E. Tissue engineering in periodontology: biological mediators for periodontal regeneration. *Int J Artif Organs*, 2019, 42(5): 241–257. <https://doi.org/10.1177/0391398819828558> PMID: 30935276
- [16] Borie E, Olivé DG, Orsi IA, Garlet K, Weber B, Beltrán V, Fuentes R. Platelet-rich fibrin application in dentistry: a literature review. *Int J Clin Exp Med*, 2015, 8(5):7922–7929. PMID: 26221349 PMCID: PMC4509294
- [17] Suchánková Kleplová T, Soukup T, Řeháček V, Suchánek J. Human plasma and human platelet-rich plasma as a substitute for fetal calf serum during long-term cultivation of mesenchymal dental pulp stem cells. *Acta Medica (Hradec Kralove)*, 2014, 57(3):119–126. <https://doi.org/10.14712/18059694.2014.50> PMID: 25649367
- [18] Dohan Ehrenfest DM, Doglioli P, de Peppo GM, Del Corso M, Charrier JB. Choukroun's platelet-rich fibrin (PRF) stimulates *in vitro* proliferation and differentiation of human oral bone mesenchymal stem cell in a dose-dependent way. *Arch Oral Biol*, 2010, 55(3):185–194. <https://doi.org/10.1016/j.archoralbio.2010.01.004> PMID: 20176344
- [19] Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol*, 2009, 27(3):158–167. <https://doi.org/10.1016/j.tibtech.2008.11.009> PMID: 19187989
- [20] Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, 1998, 85(6):638–646. [https://doi.org/10.1016/s1079-2104\(98\)90029-4](https://doi.org/10.1016/s1079-2104(98)90029-4) PMID: 9638695
- [21] Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. *J Oral Maxillofac Surg*, 1997, 55(11):1294–1299. [https://doi.org/10.1016/s0278-2391\(97\)90187-7](https://doi.org/10.1016/s0278-2391(97)90187-7) PMID: 9371122
- [22] do Amaral RJFC, da Silva NP, Haddad NF, Lopes LS, Ferreira FD, Filho RB, Cappelletti PA, de Mello W, Cordeiro-Spinetti E, Balduino A. Platelet-rich plasma obtained with different anticoagulants and their effect on platelet numbers and mesenchymal stromal cells behavior *in vitro*. *Stem Cells Int*, 2016, 2016:7414036. <https://doi.org/10.1155/2016/7414036> PMID: 27340410 PMCID: PMC4909912
- [23] Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. *Am J Sports Med*, 2009, 37(11):2259–2272. <https://doi.org/10.1177/0363546509349921> PMID: 19875361
- [24] Taylor DW, Petrera M, Hendry M, Theodoropoulos JS. A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries. *Clin J Sport Med*, 2011, 21(4):344–352. <https://doi.org/10.1097/JSM.0b013e31821d0f65> PMID: 21562414
- [25] Fujioka-Kobayashi M, Miron RJ, Hernandez M, Kandalam U, Zhang Y, Choukroun J. Optimized platelet-rich fibrin with the low-speed concept: growth factor release, biocompatibility, and cellular response. *J Periodontol*, 2017, 88(1):112–121. <https://doi.org/10.1902/jop.2016.160443> PMID: 27587367
- [26] Kawase T. Platelet-rich plasma and its derivatives as promising bioactive materials for regenerative medicine: basic principles and concepts underlying recent advances. *Odontology*, 2015, 103(2):126–135. <https://doi.org/10.1007/s10266-015-0209-2> PMID: 26040505

- [27] Lundquist R, Dziegiel MH, Agren MS. Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin. *Wound Repair Regen*, 2008, 16(3):356–363. <https://doi.org/10.1111/j.1524-475X.2007.00344.x> PMID: 18282265
- [28] Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: Technological concepts and evolution. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, 2006, 101(3):e37–e44. <https://doi.org/10.1016/j.tripleo.2005.07.008> PMID: 16504849
- [29] Ghanaati S, Booms P, Orlowska A, Kubesch A, Lorenz J, Rutkowski J, Landes C, Sader R, Kirkpatrick C, Choukroun J. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. *J Oral Implantol*, 2014, 40(6):679–689. <https://doi.org/10.1563/aaaid-joi-D-14-00138> PMID: 24945603
- [30] Kawase T, Tanaka T. An updated proposal for terminology and classification of platelet-rich fibrin. *Regen Ther*, 2017, 7:80–81. <https://doi.org/10.1016/j.reth.2017.10.002> PMID: 30271855 PMCID: PMC6153447
- [31] Panda S, Doraiswamy J, Malaippan S, Varghese SS, Del Fabbro M. Additive effect of autologous platelet concentrates in treatment of intrabony defects: a systematic review and meta-analysis. *J Investig Clin Dent*, 2016, 7(1):13–26. <https://doi.org/10.1111/jicd.12117> PMID: 25048153
- [32] Kraus MH, Pierce JH, Fleming TP, Robbins KC, Di Fiore PP, Aaronson SA. Mechanisms by which genes encoding growth factors and growth factor receptors contribute to malignant transformation. *Ann N Y Acad Sci*, 1988, 551:320–335; discussion 336. <https://doi.org/10.1111/j.1749-6632.1988.tb22358.x> PMID: 3072902
- [33] Massagué J. Transforming growth factors. Isolation, characterization, and interaction with cellular receptors. *Prog Med Virol*, 1985, 32:142–158. PMID: 2991987
- [34] Choukroun J, Ghanaati S. Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrates advances patients' own inflammatory cells, platelets and growth factors: the first introduction to the low speed centrifugation concept. *Eur J Trauma Emerg Surg*, 2018, 44(1):87–95. <https://doi.org/10.1007/s00068-017-0767-9> PMID: 28283682 PMCID: PMC5808086
- [35] Kim S, Garcia A, Jackson SP, Kunapuli SP. Insulin-like growth factor-1 regulates platelet activation through PI3-K α isoform. *Blood*, 2007, 110(13):4206–4213. <https://doi.org/10.1182/blood-2007-03-080804> PMID: 17827385 PMCID: PMC2234779
- [36] Walsh TG, Metharom P, Berndt MC. The functional role of platelets in the regulation of angiogenesis. *Platelets*, 2015, 26(3):199–211. <https://doi.org/10.3109/09537104.2014.909022> PMID: 24832135
- [37] Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. *Int J Lab Hematol*, 2013, 35(3):254–261. <https://doi.org/10.1111/ijlh.12084> PMID: 23590652
- [38] Varela HA, Souza JCM, Nascimento RM, Araújo RF Jr, Vasconcelos RC, Cavalcante RS, Guedes PM, Araújo AA. Injectable platelet rich fibrin: cell content, morphological, and protein characterization. *Clin Oral Investig*, 2019, 23(3):1309–1318. <https://doi.org/10.1007/s00784-018-2555-2> PMID: 30003342
- [39] Soloviev DA, Hazen SL, Szpak D, Bledzka KM, Ballantyne CM, Plow EF, Pluskota E. Dual role of the leukocyte integrin α M β 2 in angiogenesis. *J Immunol*, 2014, 193(9):4712–4721. <https://doi.org/10.4049/jimmunol.1400202> PMID: 25261488 PMCID: PMC4201972
- [40] Pirraco RP, Reis RL, Marques AP. Effect of monocytes/macrophages on the early osteogenic differentiation of hBMSCs. *J Tissue Eng Regen Med*, 2013, 7(5):392–400. <https://doi.org/10.1002/term.535> PMID: 22392849
- [41] Wang X, Zhang Y, Choukroun J, Ghanaati S, Miron RJ. Behavior of gingival fibroblasts on titanium implant surfaces in combination with either injectable-PRF or PRP. *Int J Mol Sci*, 2017, 18(2):331. <https://doi.org/10.3390/ijms18020331> PMID: 28165420 PMCID: PMC5343867
- [42] Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandam U, Zhang Y, Ghanaati S, Choukroun J. Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry? *Clin Oral Investig*, 2017, 21(8):2619–2627. <https://doi.org/10.1007/s00784-017-2063-9> PMID: 28154995
- [43] Hong S, Chen W, Jiang B. A comparative evaluation of concentrated growth factor and platelet-rich fibrin on the proliferation, migration, and differentiation of human stem cells of the apical papilla. *J Endod*, 2018, 44(6):977–983. <https://doi.org/10.1016/j.joen.2018.03.006> PMID: 29703620
- [44] Saeed MA, El-Rahman MA, Helal ME, Zaher AR, Grawish ME. Efficacy of human platelet rich fibrin exudate vs fetal bovine serum on proliferation and differentiation of dental pulp stem cells. *Int J Stem Cells*, 2017, 10(1):38–47. <https://doi.org/10.15283/ijsc16067> PMID: 28215057 PMCID: PMC5488775
- [45] Vogel JP, Szalay K, Geiger F, Kramer M, Richter W, Kasten P. Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and *in vivo* bone formation in calcium phosphate ceramics. *Platelets*, 2006, 17(7):462–469. <https://doi.org/10.1080/09537100600758867> PMID: 17074722
- [46] Wang Z, Weng Y, Lu S, Zong C, Qiu J, Liu Y, Liu B. Osteoblastic mesenchymal stem cell sheet combined with Choukroun platelet-rich fibrin induces bone formation at an ectopic site. *J Biomed Mater Res B Appl Biomater*, 2015, 103(6):1204–1216. <https://doi.org/10.1002/jbm.b.33288> PMID: 25327691
- [47] Ding L, Tang S, Liang P, Wang C, Zhou PF, Zheng L. Bone regeneration of canine peri-implant defects using cell sheets of adipose-derived mesenchymal stem cells and platelet-rich fibrin membranes. *J Oral Maxillofac Surg*, 2019, 77(3):499–514. <https://doi.org/10.1016/j.joms.2018.10.018> PMID: 30476490
- [48] Karde PA, Sethi KS, Mahale SA, Khedkar SU, Patil AG, Joshi CP. Comparative evaluation of platelet count and antimicrobial efficacy of injectable platelet-rich fibrin with other platelet concentrates: an *in vitro* study. *J Indian Soc Periodontol*, 2017, 21(2):97–101. https://doi.org/10.4103/jisp.jisp_201_17 PMID: 29398852 PMCID: PMC5771122
- [49] Thanasisuebwong P, Surarit R, Bencharit S, Ruangsawasdi N. Influence of fractionation methods on physical and biological properties of injectable platelet-rich fibrin: an exploratory study. *Int J Mol Sci*, 2019, 20(7):1657. <https://doi.org/10.3390/ijms20071657> PMID: 30987117 PMCID: PMC6479392
- [50] Albilia JB, Herrera-Vizcaíno CH, Weisleder H, Choukroun J, Ghanaati S. Liquid platelet-rich fibrin injections as a treatment adjunct for painful temporomandibular joints: preliminary results. *Cranio*, 2018 Sep 20, 1–13. <https://doi.org/10.1080/08869634.2018.1516183> PMID: 30231809
- [51] Chenchev IL, Ivanova VV, Neychev DZ, Cholakova RB. Application of platelet-rich fibrin and injectable platelet-rich fibrin in combination of bone substitute material for alveolar ridge augmentation – a case report. *Folia Med (Plovdiv)*, 2017, 59(3):362–366. <https://doi.org/10.1515/folmed-2017-0044> PMID: 28976904
- [52] Gülgen U, Dereci Ö. Evaluation of new bone formation in sinus floor augmentation with injectable platelet-rich fibrin-soaked collagen plug: a pilot study. *Implant Dent*, 2019, 28(3):220–225. <https://doi.org/10.1097/ID.0000000000000883> PMID: 31124818
- [53] El Raouf MA, Wang X, Miusi S, Chai J, El-Aal ABMA, Helmy MMN, Ghanaati S, Choukroun J, Choukroun E, Zhang Y, Miron RJ. Injectable-platelet rich fibrin using the low speed centrifugation concept improves cartilage regeneration when compared to platelet-rich plasma. *Platelets*, 2019, 30(2):213–221. <https://doi.org/10.1080/09537104.2017.1401058> PMID: 29240523
- [54] Wang X, Zhang Y, Choukroun J, Ghanaati S, Miron RJ. Effects of an injectable platelet-rich fibrin on osteoblast behavior and bone tissue formation in comparison to platelet-rich plasma. *Platelets*, 2018, 29(1):48–55. <https://doi.org/10.1080/09537104.2017.1293807> PMID: 28351189
- [55] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, Deans RJ, Keating A, Prockop DJ, Horwitz EM. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*, 2006, 8(4):315–317. <https://doi.org/10.1080/14653240600855905> PMID: 16923606
- [56] Páll E, Florea A, Sorîţău O, Cenariu M, Petruţiu AS, Roman A. Comparative assessment of oral mesenchymal stem cells isolated from healthy and diseased tissues. *Microsc Microanal*, 2015, 21(5):1249–1263. <https://doi.org/10.1017/S1431927615014749> PMID: 26315895
- [57] Weissgerber TL, Milic NM, Winham SJ, Garovic VD. Beyond bar and line graphs: time for a new data presentation paradigm. *PLoS Biol*, 2015, 13(4):e1002128. <https://doi.org/10.1371/journal.pbio.1002128> PMID: 25901488 PMCID: PMC4406565

- [58] Verma UP, Yadav RK, Dixit M, Gupta A. Platelet-rich fibrin: a paradigm in periodontal therapy – a systematic review. *J Int Soc Prev Community Dent*, 2017, 7(5):227–233. https://doi.org/10.4103/jispcd.JISPCD_429_16 PMID: 29026693 PMCID: PMC5629849
- [59] Martínez CE, Gómez R, Kalergis AM, Smith PC. Comparative effect of platelet-rich plasma, platelet-poor plasma, and fetal bovine serum on the proliferative response of periodontal ligament cell subpopulations. *Clin Oral Invest*, 2019, 23(5):2455–2463. <https://doi.org/10.1007/s00784-018-2637-1> PMID: 30311062
- [60] Wen J, Li HT, Li SH, Li X, Duan JM. Investigation of modified platelet-rich plasma (mPRP) in promoting the proliferation and differentiation of dental pulp stem cells from deciduous teeth. *Braz J Med Biol Res*, 2016, 49(10):e5373. <https://doi.org/10.1590/1414-431X20165373> PMID: 27599200 PMCID: PMC5018690
- [61] Duan J, Kuang W, Tan J, Li H, Zhang Y, Hirota K, Tadashi K. Differential effects of platelet rich plasma and washed platelets on the proliferation of mouse MSC cells. *Mol Biol Rep*, 2011, 38(4):2485–2490. <https://doi.org/10.1007/s11033-010-0385-7> PMID: 21140227
- [62] Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. *Growth Factors*, 2009, 27(1):63–69. <https://doi.org/10.1080/08977190802636713> PMID: 19089687
- [63] Lee UL, Jeon SH, Park JY, Choung PH. Effect of platelet-rich plasma on dental stem cells derived from human impacted third molars. *Regen Med*, 2011, 6(1):67–79. <https://doi.org/10.2217/rme.10.96> PMID: 21175288
- [64] Lykov AP, Bondarenko NA, Surovtseva MA, Kim II, Poveshchenko OV, Pokushalov EA, Kononov VI. Comparative effects of platelet-rich plasma, platelet lysate, and fetal calf serum on mesenchymal stem cells. *Bull Exp Biol Med*, 2017, 163(6):757–760. <https://doi.org/10.1007/s10517-017-3897-5> PMID: 29063326
- [65] Komori T. Regulation of bone development and extracellular matrix protein genes by *RUNX2*. *Cell Tissue Res*, 2010, 339(1):189–195. <https://doi.org/10.1007/s00441-009-0832-8> PMID: 19649655
- [66] Niu L, Sun J, Li Q, Jiao K, Shen L, Wu D, Tay F, Chen J. Intrafibrillar-silicified collagen scaffolds enhance the osteogenic capacity of human dental pulp stem cells. *J Dent*, 2014, 42(7):839–849. <https://doi.org/10.1016/j.jdent.2014.03.016> PMID: 24705068
- [67] Luu HH, Song WX, Luo X, Manning D, Luo J, Deng ZL, Sharff KA, Montag AG, Haydon RC, He TC. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. *J Orthop Res*, 2007, 25(5):665–677. <https://doi.org/10.1002/jor.20359> PMID: 17290432
- [68] El-Sayed KMF, Dörfer CE. Gingival mesenchymal stem/progenitor cells: a unique tissue engineering gem. *Stem Cells Int*, 2016, 2016:7154327. <https://doi.org/10.1155/2016/7154327> PMID: 27313628 PMCID: PMC4903147
- [69] Tomar GB, Srivastava RK, Gupta N, Barhanpurkar AP, Pote ST, Jhaveri HM, Mishra GC, Wani MR. Human gingiva-derived mesenchymal stem cells are superior to bone marrow-derived mesenchymal stem cells for cell therapy in regenerative medicine. *Biochem Biophys Res Commun*, 2010, 393(3):377–383. <https://doi.org/10.1016/j.bbrc.2010.01.126> PMID: 20138833
- [70] Qi X, Li TG, Hao J, Hu J, Wang J, Simmons H, Miura S, Mishina Y, Zhao GQ. *BMP4* supports self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways. *Proc Natl Acad Sci U S A*, 2004, 101(16):6027–6032. <https://doi.org/10.1073/pnas.0401367101> PMID: 15075392 PMCID: PMC395917
- [71] Rodríguez-Carballo E, Gámez B, Ventura F. p38 MAPK signaling in osteoblast differentiation. *Front Cell Dev Biol*, 2016, 4:40. <https://doi.org/10.3389/fcell.2016.00040> PMID: 27200351 PMCID: PMC4858538
- [72] Arpornmaeklong P, Kochel M, Depprich R, Kübler NR, Würzler KK. Influence of platelet-rich plasma (PRP) on osteogenic differentiation of rat bone marrow stromal cells. An *in vitro* study. *Int J Oral Maxillofac Surg*, 2004, 33(1):60–70. <https://doi.org/10.1054/ijom.2003.0492> PMID: 14690661
- [73] Lucarelli E, Beccheroni A, Donati D, Sangiorgi L, Cenacchi A, Del Vento AM, Meotti C, Bertoja AZ, Giardino R, Fomasari PM, Mercuri M, Picci P. Platelet-derived growth factors enhance proliferation of human stromal stem cells. *Biomaterials*, 2003, 24(18):3095–3100. [https://doi.org/10.1016/s0142-9612\(03\)00114-5](https://doi.org/10.1016/s0142-9612(03)00114-5) PMID: 12895582

Corresponding author

Carmen Mihaela Mihiu, Professor, MD, PhD, Discipline of Histology, Department of Morphological Sciences, Iuliu Hațieganu University of Medicine and Pharmacy, 4–6 Louis Pasteur Street, 400349 Cluj-Napoca, Cluj County, Romania; Phone +40727–305 085, e-mail: carmenmihiu2004@yahoo.com

Received: November 18, 2019

Accepted: July 20, 2020